Lipoplatin Formulation Review Article
Journal of Drug Delivery · 29.08.2012 · 2012 · 1-10
DOI: 10.1155/2012/581363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Drug Delivery, erschienen am 29.08.2012. Verfasst von G P Stathopoulos und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece. Die Arbeit wurde bisher 178-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Patented platform technologies have been used for the liposomal encapsulation of cisplatin (Lipoplatin) into tumor-targeted 110 nm (in diameter) nanoparticles. The molecular mechanisms, preclinical and clinical data concerning lipoplatin, are reviewed here. Lipoplatin has been successfully administered in three randomized Phase II and III clinical trials. The clinical data mainly include non-small-cell lung cancer but also pancreatic, breast, and head and neck cancers. It is anticipated that lipoplatin will replace cisplatin as well as increase its potential applications. For the first time, a platinum drug has shown superiority to cisplatin, at least in non-squamous non-small-cell lung cancer as reported in a Phase III study which documented a simultaneous lowering of all of the side effects of cisplatin.
Autor:innen und Institutionen
- First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece.
Zitieren
APA
Stathopoulos, G. P., & Boulikas, T. (2012). Lipoplatin Formulation Review Article. Journal of Drug Delivery, 2012, 1-10. https://doi.org/10.1155/2012/581363
Vancouver
Stathopoulos GP, Boulikas T. Lipoplatin Formulation Review Article. Journal of Drug Delivery. 2012;2012:1-10. doi:10.1155/2012/581363
BibTeX
@article{Stathopoulos2012,
author = {Stathopoulos, G P and Boulikas, T},
title = {Lipoplatin Formulation Review Article},
journal = {Journal of Drug Delivery},
year = {2012},
volume = {2012},
pages = {1--10},
doi = {10.1155/2012/581363}
}
EUVIMED